Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 318 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Lexapro Clear all
Completed Phase 2 Interventional Results available

Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder

NCT01469377
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, Cariprazine
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
819 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
39
States / cities
Garden Grove, California • National City, California • Oceanside, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Oct 22, 2026, 4:34 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Effects of Antidepressant Therapy on Brain Dopamine Transporter Activity in People With Major Depression

NCT00655057
View directory record Official record
Conditions
Depression
Interventions
S-citalopram, Cognitive behavioral therapy (CBT), TRODAT-1 single photon emission computed tomographic (SPECT) imaging
Drug · Behavioral · Procedure
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 16, 2020 · Synced Oct 22, 2026, 4:34 PM EDT
Active, not recruiting Early Phase 1 Interventional

Effects of Intravenous (IV) Citalopram Hydrochloride During Transcranial Magnetic Stimulation in Major Depressive Disorder (MDD)

NCT04846829
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, intermittent theta burst stimulation, intravenous citalopram hydrochloride (CIT), continuous theta burst stimulation
Drug · Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 22, 2026, 4:34 PM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)

NCT01360866
View directory record Official record
Conditions
Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders, Mental Disorders
Interventions
OPC-34712, Escitalopram, Fluoxetine, Paroxetine CR, Sertraline, Duloxetine, Venlafaxine XR
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
2,944 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
93
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 90 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2018 · Synced Oct 22, 2026, 4:34 PM EDT
Completed Phase 2 Interventional

Predicting Alcoholics' Treatment Responses to a Selective Serotonin Re-uptake Inhibitor (SSRI)

NCT00249405
View directory record Official record
Conditions
Alcoholism, Alcohol Abuse
Interventions
Citalopram + MI, Placebo + MI
Drug · Behavioral
Lead sponsor
University of Cincinnati
Other
Eligibility
21 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 3, 2010 · Synced Oct 22, 2026, 4:34 PM EDT
Completed Phase 4 Interventional

Predicting Treatment Response in Patients With OCD

NCT03993535
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
selective serotonin reuptake inhibitor
Drug
Lead sponsor
University of Sao Paulo
Other
Eligibility
18 Years to 50 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 22, 2026, 4:34 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

p11 Protein Levels in Patients With Major Depressive Disorder Treated With Citalopram

NCT00697268
View directory record Official record
Conditions
Depression
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 22, 2026, 4:34 PM EDT
Completed Phase 2 Interventional Results available

Brain Function and Structure in Cocaine Dependence

NCT02080832
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Citalopram, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 50 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 26, 2017 · Synced Oct 22, 2026, 4:34 PM EDT
Completed Not applicable Interventional Results available

A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity

NCT02655354
View directory record Official record
Conditions
Posttraumatic Stress Disorder, Depression, Alcohol-Related Disorders, Suicidal Ideation, Substance-Related Disorders, Mild Cognitive Impairment, Quality of Life, Pain, Wounds and Injury, Brain Injuries, Chronic Disease
Interventions
Motivational Interviewing, Cognitive Behavioral Therapy Elements, Care Management, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline, Citalopram, Venlafaxine, Duloxetine, Mirtazapine, Diphenhydramine, Trazodone, Prazosin
Behavioral · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
635 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
24
States / cities
Scottsdale, Arizona • Beverly Hills, California • Sacramento, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2021 · Synced Oct 22, 2026, 4:34 PM EDT
Completed Phase 2 Interventional

Serotonin, Impulsivity, and Cocaine Dependence Treatment

NCT00297505
View directory record Official record
Conditions
Cocaine Dependence
Interventions
citalopram
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 50 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 22, 2026, 4:34 PM EDT
Completed Phase 2Phase 3 Interventional

Treatment of SSRI-Resistant Depression In Adolescents (TORDIA)

NCT00018902
View directory record Official record
Conditions
Depression
Interventions
Fluoxetine, Venlafaxine, Cognitive Behavioral Therapy (CBT), Citalopram
Drug · Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
12 Years to 18 Years
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
6
States / cities
Los Angeles, California • Portland, Oregon • Pittsburgh, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2014 · Synced Oct 22, 2026, 4:34 PM EDT
Completed Phase 3 Interventional

Escitalopram (Lexapro®) In Patients With Major Depression With Atypical Features

NCT00610506
View directory record Official record
Conditions
Atypical Depression
Interventions
Escitalopram
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 31, 2013 · Synced Oct 22, 2026, 4:34 PM EDT
Withdrawn Phase 2 Interventional

Neuroimaging Predictors of Antidepressant Treatment Outcome

NCT02000726
View directory record Official record
Conditions
Depression
Interventions
Placebo, Citalopram, Fast acting antidepressant-like treatment. administered i.v. during the fMRI scanning session
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 21, 2016 · Synced Oct 22, 2026, 4:34 PM EDT
Completed Phase 4 Interventional Results available

Combination Treatment Study for Memory Impairment and Depression

NCT01658228
View directory record Official record
Conditions
Depression, Mild Cognitive Impairment
Interventions
Donepezil, Placebo, Citalopram, Venlafaxine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
55 Years to 95 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
New York, New York • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 17, 2017 · Synced Oct 22, 2026, 4:34 PM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy of Vilazodone in Major Depressive Disorder

NCT01473381
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Vilazodone, Placebo to citalopram, Placebo to vilazodone, Citalopram
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
54
States / cities
Birmingham, Alabama • Dothan, Alabama • Scottsdale, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2014 · Synced Oct 22, 2026, 4:34 PM EDT
Completed Phase 4 Interventional Results available

A Study Comparing Duloxetine to Other Antidepressants in the Treatment of Severe Depression

NCT00666757
View directory record Official record
Conditions
Depression
Interventions
duloxetine, fluoxetine, citalopram, paroxetine, sertraline
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
61
States / cities
Carson, California • Irvine, California • San Diego, California + 58 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2010 · Synced Oct 22, 2026, 4:34 PM EDT
Completed Phase 2 Interventional

SAT vs Escitalopram for Rectal Hypersensitivity

NCT00584571
View directory record Official record
Conditions
Rectal Hypersensitivity, Irritable Bowel Syndrome-Constipation
Interventions
Sensory Adaptation Training, Escitalopram Therapy
Procedure · Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
2
States / cities
Augusta, Georgia • Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Oct 22, 2026, 4:34 PM EDT
Recruiting Phase 2 Interventional

Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression

NCT06591091
View directory record Official record
Conditions
Depression
Interventions
Clemastine Fumarate, Placebo
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
60 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 22, 2026, 4:34 PM EDT
Completed Not applicable Interventional

Antidepressant Treatment in Older Adults With Schizophrenia

NCT00047450
View directory record Official record
Conditions
Schizophrenia
Interventions
Citalopram (Celexa), Placebo
Drug
Lead sponsor
Veterans Medical Research Foundation
Other
Eligibility
40 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
2
States / cities
San Diego, California • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 9, 2013 · Synced Oct 22, 2026, 4:34 PM EDT
Completed Phase 3 Interventional Results available

A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder

NCT04476030
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
SAGE-217, Matching Placebo, Sertraline, Escitalopram, Citalopram, Duloxetine, Desvenlafaxine
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 64 Years
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
51
States / cities
Dothan, Alabama • Phoenix, Arizona • Anaheim, California + 42 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2023 · Synced Oct 22, 2026, 4:34 PM EDT
Completed Phase 4 Interventional

Escitalopram for the Treatment of Self-Injurious Skin Picking

NCT00115011
View directory record Official record
Conditions
Impulse Control Disorders
Interventions
Escitalopram
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 20, 2008 · Synced Oct 22, 2026, 4:34 PM EDT
Completed Phase 3 Interventional

Effects of Antidepressants on Sexual Functioning

NCT00051259
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
Extended-Release Bupropion Hydrochloride
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
23
States / cities
Berkeley, California • Beverly Hills, California • La Mesa, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2010 · Synced Oct 22, 2026, 4:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Aripiprazole and Lexapro Drug Interaction Study

NCT00361790
View directory record Official record
Conditions
Healthy
Interventions
Escitalopram on days -7 to day 14; Aripiprazole dosed starting Day 1 to day 14: 3 days at 10 mg, 4 days at 15 mg and 7 days at 20 mg
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 8, 2013 · Synced Oct 22, 2026, 4:34 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) vs. Escitalopram in Postmenopausal Women

NCT00406640
View directory record Official record
Conditions
Depression, Depressive Disorder, Depressive Disorder, Major
Interventions
Desvenlafaxine succinate sustained-release (DVS SR), Escitalopram
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
52
States / cities
Peoria, Arizona • Pasadena, California • San Diego, California + 46 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2023 · Synced Oct 22, 2026, 4:34 PM EDT